Skip to main content
main-content

Genitourinary cancers

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Immunotherapy-related AEs reviewed, underlying mechanism postulated

Cancer cell

Researchers have comprehensively analyzed the incidence of adverse events in trials of PD-1 and PD-L1 inhibitors, while another team has provided insight into the potential pathophysiologic process underlying these effects.

Expert video interview

Adjuvant chemotherapy for upper tract urothelial cancer

(Neo)adjuvant therapy for upper tract urothelial cancer (video)

Dr Alison Birtle (Rosemere Cancer Centre, Royal Preston Hospital, UK) discusses the rationale for adjuvant chemotherapy for upper tract urothelial cancer (UTUC), the POUT trial and its practice-changing implications for treatment of UTUC.

medwireNews top story

Second-line atezolizumab feasible for advanced urothelial carcinoma with comorbidity

IV drip

Results from the SAUL study add support for the use of atezolizumab in patients with advanced urothelial or nonurothelial carcinoma of the urinary tract, including those with autoimmune disease and other comorbidities.

medwireNews top story

Adjuvant testicular cancer treatment may not adversely affect sperm count, concentration

Human sperm

One course of adjuvant chemotherapy or radiotherapy does not appear to have a negative effect on sperm count or concentration over the long term in men with clinical stage I testicular cancer, suggests research.

medwireNews top story

Sex disparity identified for hyperprogressive disease after immunotherapy

Male & female outlines_chalk

Women may be at greater risk than men for experiencing hyperprogression as a response to cancer treatment with immune checkpoint inhibitors, say researchers.

medwireNews top story

Immunotherapy-based regimens show promise in non-clear-cell RCC

Human kidney cross section

Three trials point to the potential of regimens incorporating agents targeting the programmed cell death protein 1 or its ligand in patients with non-clear-cell renal cell carcinoma.

medwireNews@ESMO2018

Genitourinary cancers coverage at the ESMO Congress 2018

Munich
Expert opinion

Bipolar androgen therapy: Progress and future directions

Bipolar androgen therapy: Progress and future directions

Michael Schweizer (University of Washington, Seattle, USA) outlines a new therapy that utilizes both androgen deprivation and administration, which may potentially have benefit for prostate cancer patients.

Expert opinion

Urinary biomarkers in the management of prostate cancer

Urinary biomarkers in the management of prostate cancer

Non-invasive biomarkers have the potential to guide and improve prostate cancer management in many ways. Maria Frantzi, Agnieszka Latosinska, and Harald Mischak (Mosaiques Diagnostics GmbH, Germany) outline some promising markers and what is needed to implement them in the clinic.

30-10-2018 | Castration-resistant prostate cancer | ESMO 2018 | Video

Abiraterone alone likely suppresses testosterone sufficiently in mCRPC patients

Carsten Ohlmann discusses findings of the phase II SPARE trial that investigated forgoing LHRH therapy in metastatic prostate cancer patients receiving abiraterone acetate (5:16).

30-10-2018 | Renal cell carcinoma | ESMO 2018 | Video

Expert comment on the JAVELIN Renal 101 trial

ESMO expert Markus Joerger gives his views on the JAVELIN Renal 101 study pitting the combination of avelumab and axitinib against sunitinib in the first-line advanced RCC setting (1:48).

03-06-2018 | Prostate cancer | ASCO 2018 | Video

Expert commentary: Unpicking the relationship between prostate cancer treatment efficacy, survival and race

ASCO Expert Robert Dreicer reviews two studies looking at differences in survival rates between Black and White men with metastatic castration-resistant prostate cancer (3:16). 

Read the accompanying news story here.

23-05-2019 | Urothelial cancer | News

Sustained nivolumab, ipilimumab activity shown in advanced urothelial cancer

Extended follow-up of patients with unresectable locally advanced or metastatic urothelial carcinoma in the CheckMate 032 trial shows sustained antitumor activity of nivolumab alone and in combination with ipilimumab.

20-05-2019 | Prostate cancer | News

Poor glycemic control linked to prostate cancer progression

In men with prostate cancer and diabetes, higher glycated hemoglobin levels are associated with an increased risk for developing metastases and castration-resistant disease, findings indicate.

17-05-2019 | FDA | News

USA approves first-line avelumab–axitinib for advanced RCC

Click through to read more

Our Editorial Board advisor

Axel S Merseburger MD

Dr Merseburger is currently Professor and Chairman of the Clinic of Urology at University Hospital Schleswig-Holstein in Lübeck, Germany, having previously served as Vice Chairman of the Department of Urologic Oncology and Director of the Urologic Oncology Programme at Hannover Medical School, Germany. Dr Merseburger’s key areas of interest are renal cell carcinoma, prostate cancer and transitional cell carcinoma, with special attention given to novel markers and prognostic factors. He is a principal investigator in German Phase II and III trials.

Expert opinion

Bipolar androgen therapy: Progress and future directions

Bipolar androgen therapy: Progress and future directions

Michael Schweizer (University of Washington, Seattle, USA) outlines a new therapy that utilizes both androgen deprivation and administration, which may potentially have benefit for prostate cancer patients.

Journal articles and book chapters

10-04-2019 | Urothelial cancer | Video | Article

Adjuvant chemotherapy for upper tract urothelial cancer

Dr Alison Birtle (Rosemere Cancer Centre, Royal Preston Hospital, UK) discusses the rationale for adjuvant chemotherapy for upper tract urothelial cancer (UTUC), the POUT trial and its practice-changing implications for treatment of UTUC.

21-08-2018 | Prostate cancer | Article

Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations

Crawford ED, Heidenreich A, Lawrentschuk N et al. Prostate Cancer Prostatic Dis 2018. doi:10.1038/s41391-018-0079-0.

29-06-2018 | Castration-resistant prostate cancer | Article

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

Hussain M et al. N Engl J Med 2018; 378(26): 2465-2474. doi:10.1056/NEJMoa1800536

28-06-2018 | PARP inhibitors | Article

Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?

Ashworth A. Lord CJ. Nat Rev Clin Oncol 2018. doi:10.1038/s41571-018-0055-6

14-06-2018 | Renal cell carcinoma | Article

An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma

Grünwald V et al. Nat Rev Urol 2018. doi:10.1038/s41585-018-0034-9.

05-06-2018 | Prostate cancer | Article

Statin use and time to progression in men on active surveillance for prostate cancer

Jayalath VH et al. Prostate Cancer Prostatic Dis 2018. doi:10.1038/s41391-018-0053-x

05-06-2018 | Radiotherapy | Article

Safety of combining radiotherapy with immune-checkpoint inhibition

Hwang WL et al. Nat Rev Clin Oncol 2018. doi: 10.1038/s41571-018-0046-7

04-06-2018 | Renal cell carcinoma | Article

Epigenetics in renal cell cancer: mechanisms and clinical applications

Joosten SC et al. Nat Rev Urol 2018. doi:10.1038/s41585-018-0023-z

Images and illustrations

12-04-2018 | Prostate cancer | Images and illustration slides | Collection

Prostate cancer imaging

This downloadable powerpoint slide set presents an overview of the imaging techniques used to assess prostate cancer from initial diagnosis and staging, to evaluation of residual or recurrent disease after treatment. These slides can be used for reference purposes or for inclusion in one’s own slide sets. Source: Vargas HA et al. Prostate Cancer Imaging. In: Bach Am, Zhang J, eds. Atlas of Genitourinary Oncological Imaging. Springer New York.

Image Credits